Now showing items 1-5 of 5
Pharmacovigilance in hospice/palliative care: rapid report of net clinical effect of metoclopramide
((C) Mary Ann Liebert, Inc., 2012-07-20)
Background: Understanding the performance of prescribed medications in day-to-day practice is important to minimize harm, maximize clinical benefits, and, eventually, better target the people who are most likely to benefit, ...
Planning phase III multi-site clinical trials in palliative care: the role of consecutive cohort audits to identify potential participant populations
Goals of Work: Multiple sites enable more successful completion of adequately powered phase III studies in palliative care. Audits of the frequency and distribution of the symptoms of interest can better inform research ...
Adverse events in hospice and palliative care: a pilot study to determine feasibility of collection and baseline rates
(Mary Ann Liebert, Inc., 2011-01-19)
Background: Continuous quality improvement is fundamental in all health care, including hospice and palliative care. Identifying and systematically reducing symptomatic adverse events is limited in hospice and palliative ...
An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice
(Mary Ann Liebert, Inc., 2012-02-21)
Background: Medication registration currently requires evidence of safety and efficacy from adequately powered phase 3 studies. Pharmacovigilance (phase 4 studies, postmarketing data, adverse drug reaction reporting) provide ...
Off-label prescribing in palliative care – a cross-sectional national survey of Palliative Medicine doctors
(SAGE Publications, 2012-11-05)
Background: Regulatory bodies including the European Medicines Agency register medications (formulation, route of administration) for specific clinical indications. Once registered, prescription is at clinicians’ discretion. ...